Cleveland-based Athersys is pocketing a $10 million upfront payment from Chugai in exchange for licensing rights to the biotech's stem cell treatment for repairing stroke damage. The Japanese pharma company, which has close relations with Roche, also stands to earn up to $45 million in development and regulatory milestones with another $150 million in sales milestones.
Today, Kite expanded its research and development deal--or CRADA--with some key researchers at the National Cancer Institute to cover additional programs and targeting tools needed to beef up its pipeline during a critical stage of development for this hotly competitive niche in the cancer arena.
China's Eddingpharm has been granted rights by Amarin to sell hypertriglyceridemia drug Vascepa icosapent ethyl in Greater China.
Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.
Chugai and U.S.-based Athersys Inc. agreed to partner in a license agreement on the development of a stem cell therapy for ischemic stroke that includes clinical trial work in Japan.
AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.
Australia-based Cynata said it is on track to manufacture mesenchymal stem cells at a commercial scale after validation of its Cymerus MSC manufacturing technology and has an eye on companies in Japan as it seeks partnerships to reach the market.
Taiwan's Twi Pharmaceuticals canceled its U.S. distribution and marketing agreement with Israel's Teva Pharmaceuticals for two generic drugs to have Twi's U.S. unit market them with its built-up sale network.
The Department of Defense has a habit of funding new medical technologies. This week it awarded a government contractor MRIGlobal $14.8 million for its proposed Sample-to-Sequence system to sequence the entire genome of pathogens and give a diagnosis within 24 hours.
Oncology company Heat Biologics is partnering with OncoSec, developer of the ImmunoPulse intratumoral DNA delivery platform. The two companies will evaluate the combination of the immunotherapy approaches developed by each company, according to the release.